Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus doxorubicin and cisplatin for stage IIB classic extremity osteosarcoma
ChiCTR2000033298Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib, doxorubicin and cisplatin in osteosarcoma (OS), sponsored by West China Hospital of Sichuan University. Primary endpoint: 24-month event-free survival rate. Started Feb 2020; status: recruiting.
02
Drugs
anlotinibdoxorubicincisplatin
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on ChiCTR2000033298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033298.